找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Case-Based Gynecological Oncology; Kavita Singh,Bindiya Gupta Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive l

[復(fù)制鏈接]
樓主: 磨損
21#
發(fā)表于 2025-3-25 06:05:53 | 只看該作者
Epithelial Ovarian Cancer: High Grade SerousEpithelial ovarian cancer mainly presents in advanced stage. In recent years, treatment has been revolutionized by changes in surgical and medical management, introduction of targeted therapies and biomarker directed therapies. This change in the treatment paradigm has had substantially improved survival statistics.
22#
發(fā)表于 2025-3-25 10:39:01 | 只看該作者
Recurrent Ovarian CancerRecurrent ovarian cancer may be sensitive to platinum or platinum resistant. Management includes a combination of chemotherapy and targeted therapy. Secondary debulking surgery can be done in select cases where it is possible to achieve complete cytoreduction..This chapter will discuss clinical scenarios of recurrent ovarian cancer.
23#
發(fā)表于 2025-3-25 14:05:11 | 只看該作者
24#
發(fā)表于 2025-3-25 16:56:49 | 只看該作者
25#
發(fā)表于 2025-3-25 20:14:28 | 只看該作者
26#
發(fā)表于 2025-3-26 02:03:09 | 只看該作者
27#
發(fā)表于 2025-3-26 05:21:12 | 只看該作者
28#
發(fā)表于 2025-3-26 11:27:07 | 只看該作者
Metastatic Ovarian Canceristochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or cytoreductive surgery may be useful.
29#
發(fā)表于 2025-3-26 13:51:58 | 只看該作者
Borderline Ovarian Tumours: Early and Advance Stage: Serous, Mucinous, Micro Invasive Cancer, Invasi mild nuclear atypia without destructive stromal invasion. These account for 10–15% of all epithelial tumours. The most common subtypes are serous and mucinous tumours. Surgery is the mainstay of management and these are associated with better prognosis than invasive carcinomas.
30#
發(fā)表于 2025-3-26 19:31:56 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 18:44
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
贵阳市| 镇平县| 滨州市| 东源县| 策勒县| 郸城县| 自治县| 丰原市| 杂多县| 眉山市| 都安| 剑阁县| 太保市| 双辽市| 阆中市| 依兰县| 渭南市| 榆树市| 治县。| 家居| 会理县| 天气| 乐至县| 正定县| 柘荣县| 万山特区| 望江县| 苏尼特左旗| 丹凤县| 阿图什市| 溆浦县| 汕尾市| 电白县| 博白县| 金川县| 黑河市| 江城| 肇东市| 雅江县| 九江市| 枞阳县|